Arrhythmogenic right ventricular cardiomyopathy type 6 (ARVC6): support for the locus assignment, narrowing of the critical region and mutation screening of three candidate genes by Matolweni, Luzuko et al.
BioMed CentralBMC Medical Genetics
ssOpen AcceResearch article
Arrhythmogenic right ventricular cardiomyopathy type 6 (ARVC6): 
support for the locus assignment, narrowing of the critical region 
and mutation screening of three candidate genes
Luzuko O Matolweni†1,2, Soraya Bardien†2,5, George Rebello2, Ekow Oppon2, 
Miroslav Munclinger3,6, Rajkumar Ramesar2, Hugh Watkins4 and 
Bongani M Mayosi*1
Address: 1The Cardiac Clinic, Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa, 2MRC/
UCT Research Unit for Human Genetics, Division of Human Genetics, Department of Clinical Laboratory Sciences, Institute of Infectious Disease 
and Molecular Medicine, University of Cape Town, Cape Town, South Africa, 3Sub-department of Cardiology, Department of Medicine, University 
of Kwa-Zulu Natal, Durban, South Africa, 4Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK, 
5Centre for Human Genetics Research and Education, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, Cape Town, South Africa 
and 6Department of Medicine and Cardiology, Mafraq Hospital, Abu Dhabi, United Arab Emirates
Email: Luzuko O Matolweni - matolwenil2@students.wits.ac.za; Soraya Bardien - sbardien@sun.ac.za; George Rebello - gr@cormack.uct.ac.za; 
Ekow Oppon - ekow@ukoyisa.co.za; Miroslav Munclinger - miroslavmunclinger@hotmail.com; Rajkumar Ramesar - rr@cormack.uct.ac.za; 
Hugh Watkins - hugh.watkins@cardiov.ox.ac.uk; Bongani M Mayosi* - bmayosi@uctgsh1.uct.ac.za
* Corresponding author    †Equal contributors
Abstract
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable disorder
characterized by progressive degeneration of right ventricular myocardium, arrhythmias and an increased
risk of sudden death at a young age. By linkage analysis, ARVC type 6 was previously mapped to a 10.6 cM
region on chromosome 10p12-p14 in a large North American kindred. To date, the genetic defect that
causes ARVC6 has not been identified.
Methods: We identified a South African family of 13 members with ARVC segregating as an autosomal
dominant disorder. The diagnosis of ARVC was based on international diagnostic criteria. All available
family members were genotyped with microsatellite markers at six known ARVC loci, and positional
candidate gene screening was performed.
Results: Genetic linkage and haplotype analysis provided lod scores that are highly suggestive of linkage
to the ARVC6 locus on chromosome 10p12-p14, and the narrowing of the critical region to ~2.9 Mb. Two
positional candidate genes (ITG8 and FRMD4A) were screened in which defects could possibly disrupt cell-
cell adhesion. A non-positional candidate gene with apoptosis inducing properties, LAMR1P6 (laminin
receptor 1 pseudogene 6) was also screened. Direct sequencing of DNA from affected individuals failed
to detect disease-causing mutations in the exonic sequences of the three genes investigated.
Conclusion: The narrowing of the ARVC6 critical region may facilitate progress towards the
identification of the gene that is involved in ARVC. Identification of the causative genes for ARVC will
contribute to the understanding of the pathogenesis and management of this poorly understood condition.
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Arrhythmogenic right ventricular cardiomyopathy
(ARVC, OMIM: 604401) is characterized by progressive
degeneration and fibro-fatty replacement of right ven-
tricular myocardium, causing ventricular tachyarrhyth-
mias and resulting in sudden death, often during exercise.
In Italy, where the condition has been studied extensively,
ARVC accounts for 20% of all sudden deaths in individu-
als under 35 years and 22% of sudden deaths in athletes
[1]. Familial occurrence is reported in 30–50% of individ-
uals with ARVC, suggesting that genetic factors may play
an aetiological role in a significant proportion of affected
people [2]. At least 11 loci have potentially been identi-
fied so far: ARVC1 (14q23-q24), ARVC2 (1q42-q43),
ARVC3 (14q12-q22), ARVC4 (2q32.1-q32.3), ARVC5
(3p23), ARVC6 (10p12-p14), chromosome 10q22.3,
ARVD8 (6p24), ARVC9 (12p11), Naxos disease (17q21),
and ARVC with anterior polar cataract [3,4]. To date five
candidate genes have been identified, i.e., ryanodine
receptor (RyR2 on 1q42), plakoglobin (JUP on 17q21),
desmoplakin (DSM on 6p24), plakophilin-2 (PKP2 on
12p11), and transforming growth factor β3 gene (TGFβ3
on 14q24.3) [4,5]. Recently, a serendipitous mouse
model of ARVC was discovered in which a functional lam-
inin 1 receptor (lamr1) retroposon interacted with hetero-
chromatin protein 1 (HP1) to cause degeneration of
cardiomyocytes in the right ventricle of the heart [6].
Several lines of evidence suggest that impairment of cell-
to-cell adhesion leading to accelerated apoptosis of myo-
cardial cells may be the underlying pathogenic mecha-
nism in ARVC. According to this hypothesis, disruption of
cellular junctional cohesion leads to cell death and repair
by fibrofatty replacement [7]. Initial support for this
hypothesis was provided by the observation of abnormal-
ities of myocyte intercalated discs on electron microscopy
[8,9]. Subsequently, the involvement of desmosomal pro-
teins (i.e., plakoglobin, desmoplakin and plakophilin-2)
in different ARVC clinical phenotypes has been reported
[7,10-12]. ARVC2, which has features that are more typi-
cal of a catecholamine-dependent ventricular tachycardia
syndrome than ARVC, is associated with a mutation in
ryanodine receptor-2 [13]. Mutations in the regulatory
regions of the TGFβ3 have been found in association with
one of the three families linked to the ARVC2 locus, and
in one isolated case of ARVC [5]. The role of TGFβ3 muta-
tions remain to be confirmed as a cause of ARVC because
of the absence of mutations in the other two families that
have been linked to this locus [4]. The difficulty in identi-
fying the genetic mutations underlying ARVC2, which was
initially mapped more than 10 years ago [14], underscore
the challenge of cloning causal genes in rare disorders
with small families, such as ARVC.
It is of interest that the discovery of the plakophilin-2 gene
on chromosome 12p11 as a cause of ARVC has resulted in
the re-assignment of the disease locus in one small Euro-
pean family. Originally, this family was thought to be
linked to chromosome 2q32.1-q33.3 using a cumulative
lod score together with two other small families [15].
Individually, these families did not produce statistically
significant lod scores. Subsequently, a frame shift muta-
tion was identified in the plakophilin-2 gene in the Euro-
pean family, which shows that the original linkage
findings to chromosome 2 in this family were erroneous
[12].
Therefore, independent corroboration of genetic linkage
findings, particularly in rare conditions such as ARVC, is
essential to facilitate progress towards the identification of
causal genetic mutations. We report on the linkage analy-
sis in a South African family with ARVC, which provided
support for previous chromosomal localization of
ARVC6, the narrowing of the critical region, and exclusion
of disease-causing mutations in the coding regions of two
positional and one non-positional candidate genes.
Methods
Family and clinical evaluation
A family with ARVC was investigated at Wentworth Hos-
pital, Durban and Groote Schuur Hospital, Cape Town,
South Africa. Family members gave informed consent to
participate in the study, which was approved by the local
ethics committee. The protocol included: 12-lead electro-
cardiogram (ECG), signal averaged ECG, 24-hour ambu-
latory ECG, and 2D echocardiogram. Additional
procedures (i.e., cardiac magnetic resonance imaging,
right ventricular angiogram, and endomyocardial biopsy)
were performed when clinically indicated. The diagnosis
in the index case was based on criteria proposed by McK-
enna et al [16]: i.e., affection status was established when
two major criteria, or one major criterion plus two minor
criteria, or four minor criteria were fulfilled. The diagnosis
of ARVC in the other family members was based on the
criteria for familial ARVC proposed by Hamid et al [2];
i.e., the presence of one or more minor criteria in the con-
text of familial ARVC indicate an affected status.
Molecular genetic studies
Peripheral blood samples were collected from family
members in EDTA-coated tubes and genomic DNA was
prepared from nucleated blood cells, according to the salt-
ing out method. PCR-based methods were used for geno-
typing and sequencing. All PCR amplifications were
carried out on a GeneAmp 9700 thermocycler (Applied
Biosystems). Each 50 µl reaction contained 200 ng of
genomic DNA, 200 µM dNTPs, 50 mM KCL, 10 mM Tris
(pH 8.4), 10 pM of each primer and 1 unit of BIOTAQ
DNA polymerase (BIOLINE). The concentration of mag-Page 2 of 10
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BMC Medical Genetics 2006, 7:29 http://www.biomedcentral.com/1471-2350/7/29Table 1: Oligonucleotide primers used for PCR amplification and DNA sequencing of the exons of the ITGA8, FRMD4A, and LAMR1P6 
genes.
Gene Exon No. PCR fragment 
size (bp)
Forward primer (5' → 3') Reverse primer (5' → 3') Melting 
temperature 
(°C)
ITGA8 1 587 acc gcc aga ttc cac cag tgggtc ttc tgg gtc ctg t 58
2 300 ggg cag gag gtt aca gag ac acc aag aca gcg gga agt c 56
3 300 gag gag ttt gac aag gat tgg gct ttc cta aac atg agc ttg 54
4 368 ggc caa tta att cac cca at tac cta ccc ccg aag ctt tt 48
5 399 tca caa cgc tat ttg gtg taa ga cag gct agg tat gtt cct caa ga 58
6 223 tct ctc aag gga gag agt tca a tgt ttg agg tga tgg tta tgc t 45
7 296 ttt caa ggg aat gtg ggt ct cat cgg ata agt cag gga ta 54
8 249 tgg tag ccc ttt cac ctt tt ctc cat taa tat ccc ttt gg 56
9 250 ata tgg cgt gtg tgt gtg tg cgg tgg att agg tgt att aag tg 54
10 238 cca att cta tgg caa atg gt tgc cta gga cag ttt cca gt 56
11 329 att cac tgg gtc agg ggt tag tga ggc aat aag gaa ggg tgt 58
12 464 taa caa agc agc gaa agc aa taa ctg cac cca cac aca cc 58
13 475 tag aga agt tga ggc agg agg atc act tg gct tca gcc tca tct gta gaa gaa aac tgc 56
14 250 acc atc agc atg tag ggg ta ccc cag aat aaa tcg ttg ga 55
15 243 Atg cag tga agt ggg ctt ct caa gat acc cag gtg atg tga a 55
16 553 ttg gta gaa ggg gtg tgt g gca tga taa atg agc tgg aa 56
17 468 ttc cag ctc att tat cat gc gaa gtc agg gtc aag agg ag 55
18 399 aca taa atc agc ctc cat cta agc cat gca gaa gta aaa atg aaa gga 56
19 278 ttt gtg gca cca ttc aga att t caa gaa ttt cac gca gca tag tt 56
20 460 gat gat tct ctt gcc tct tcc tac gtg gct cat tgc tgt tat gat tta 56
21 299 ctc ctg ggt gtt tga gat cc agg tgc tga gtt gct gag tg 58
22 244 ggg ttt tgc agg aat gac tt aag ggc ctt gac aga tga c 58
23 268 cgt gtg ttc tcc tgt gat atg cat cag gaa aat tcc aca tca 55
24 324 gaa aac cac ttt ctt ctg ctt c cac agc gag atc ctg tct ca 56
25 396 tgc cat atc gac ttt gaa tt aat caa caa agc cac tga 55
26 369 cac agg tct gga tcc tca tgt tga gca ctg aag gag acc aa 58
27 298 ggt gat gac ttt tga gga aat ga cgc tat gaa aag act tcc cac t 58
28 263 att agg tgg ctg cca gta taa c acc act aaa gcc tag cac aag c 56
29 380 gga tcc ttt cag atc aac ttc c gca aac aag aca cga ttt tcc 56
30 365 ctg ggg aat aga gag cga gac gtg cgg tgt aga tga ggt gat 58
FRMD4A 1 597 acc tcc tat gcc tcc ctg aa ctg gca gca att ctt cct tt 58
2 371 cac agt tcc cac cct gtc tt aaa gag cct gcg gga taa ag 58
3 395 ata cag tgc cga ctc cca ga gga tgc ctt agg ctg gtg ta 58
4 387 gac cct tga ctt ggc tgt gt caa gtg gtc tgc agc tga tt 58
FRMD4A splice 
variant
1 688 ggt gag cat gtg acc tac tgt cca act gtt cag gaa acg tg 58
nested primers gc gtg act tgc atg atg tga c ccc aag cct tat agc act aaa c
LAMR1P6 1 884 ttc cca tcg caa ctt aaa gg caa cgt tgt ttc cat gtt gc 58
nested primers aca gag caa tgg tgg gaa ag ctt tcc cac cat tgc tct gt
nested primers aat tgc tgg cca ctt cac tc caa ctg cat caa acc cac tg
nesium chloride was varied depending on the GC content
of the primers used. The PCR protocol required an initial
denaturation step of 2 minutes at 95°C, followed by 25
cycles of denaturation at the same temperature, annealing
at different temperatures depending on primer character-
istics, and extension at 72°C for 1 minute. A final exten-
sion step for 2 minutes was included. The duration and
temperature profiles for the annealing cycle segments
were altered depending on the primer sequence and type
of application (e.g., genotyping or sequencing). For visu-
alization of the PCR product in non automated and auto-
mated systems, ethidium bromide or fluorescently-
labeled primers were used, respectively. Both the ABI
PRISM model 377 and 3100 genetic analyzers from
Applied Biosystems were used in the genotyping and
sequencing experiments.Page 3 of 10
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PCR primer sequences for the different genetic markers
were obtained from the Genome Database [17]. The fol-
lowing markers were used to assess linkage to the follow-
ing ARVD loci: ARVD1 – D14S42, D14S999; ARVD2 –
D1S2925, D1S180; ARVD3 – D14S252, D14S80; ARVD4
– D2S364, D2S389, ARVD5 – D3S1259, D3S1293, and
ARVD6 – D10S464, D10S547, D10S1705, D10S2325,
D10S1707, D10S1664, D10S191, D10S1653, D10S1477,
D10S1661, D10S504, D10S2318, D10S548, D10S466,
D10S245. Two point lod scores were calculated using the
MLINK program of the LINKAGE package (version 5.10).
The program parameters were set for that of an autosomal
dominant inherited disorder at two levels of penetrance:
60% and 95%. The allele frequencies for the normal and
disease alleles were set at 0.9999 and 0.0001, respectively.
Haplotypes in the pedigree were constructed using the
Genehunter program [version 2.0 beta (r2)]. Genetic dis-
tances (in centiMorgans) between markers and the order
of the markers, which were specified for the construction
of haplotypes, were determined from the Marshfield [18],
the University of California Santa Cruz [19], and
LocusLink [20] databases.
Bioinformatic analysis of the ARVD 6 critical region
The genomic sequence for the ARVD6 critical region
between markers D10S1707 and D10S1477 was down-
loaded from the UCSC Genome Browser [assembly:
Human Nov 2002]. A comparative analysis of the
sequence with that from the National Center for Biotech-
nology Information (NCBI) non-redundant database was
performed using the option blastn [21] to detect possible
contaminating sequences from other chromosomes.
LocusLink was used to determine the gene structure of
Table 2: Clinical features of affected members with familial arrhythmogenic right ventricular cardiomyopathy.
Subject Age at 
diagnosis 
(yrs.)
Sex Clinical 
presentation
ECG and EPS 
abnormalities
RV abnormalities on 
imaging studies
Pathological 
findings on 
endomyocard
ial biopsy or 
autopsy
Major criteria Minor criteria
II:4 44 F Asymptomatic T wave inversion V1-
3
None found on echo 
MRI not done
Not 
performed
0 2
II:7 44 F Palpitations T wave inversion V1-
3
Mild right ventricular 
dilation with wall 
motion change and 
aneurismal abnormality 
on MRI
Not 
performed
0 3
III:2 16 M Palpitations T wave inversion V1-
3 Epsilon wave, V1 
VT with LBBB 
morphology 
Inducible VT
Dilated RV with 
hypokinetic outflow 
tract
Not 
performed
2 2
III:3 13 F Palpitations VT with LBBB 
morphology
Dilated RV with 
hypokinesia
Not 
performed
1 2
III:4 23 M Palpitations, 
chest pain
T-wave inversion V1-
5 PVCs with LBBB 
pattern
Dilated RV on echo Fibrofatty 
replacement 
of RV 
myocardium 
on 
endomyocard
ial biopsy
1 4
III:6 21 M Asymptomatic Dilated RV on echo; 
Evidence of fatty 
infiltration of RV wall 
on MRI
Not 
performed
1 2
III:7 19 F Syncope Frequent PVCs 
(>1000/24hrs)
Dilated RV on echo 
and MRI; Fatty 
infiltration of RV wall 
on MRI
Not 
performed
1 4
III:9 16 F Asymptomatic None Mild right ventricular 
dilation with wall 
motion change and 
aneurismal abnormality 
on MRI
Not 
performed
0 2
Note: Echo, echocardiography; ECG, electrocardiogram; EPS, electrophysiological study; F, female; LBBB, left bundle branch block; M, male; MRI, 
magnetic resonance imaging; RV, right ventricle; VT, ventricular tachycardia; PVCs, premature ventricular complexes.Page 4 of 10
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brate Genome Annotation database was used for the
LAMR1P6 pseudogene. The genes in the critical region
were positioned relative to the microsatellite markers.
Information about the expression and putative gene func-
tion of the genes was obtained from various databases
linked to the University of California Santa Cruz genome
database [19], LocusLink [22], Gene Ontology [22], Gene
Cards [23], and Stanford SOURCE [24].
Mutation screening of the candidate genes
The majority of the genes (e.g., desmoplakin, plakoglobin
and plakophilin-2) that cause ARVC code for proteins that
are involved in cell-cell adhesion. For this reason, genes
Pedigree of the ARVC family studied, showing pedigree numbers by generation and person number (i.e., I:1 to III:9), and geno-types useful for delimiting crossov r pointsFigu  1
Pedigree of the ARVC family studied, showing pedigree numbers by generation and person number (i.e., I:1 to III:9), and geno-
types useful for delimiting crossover points. Markers names at the left of each generation. Individuals III:7 and III:9 have recom-
binations that delimit the region. The disease-associated haplotype is shaded in black. Genotypes for individual I:1 are inferred.
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to-cell adhesion were prioritized for mutation screening.
Annotated genomic sequence of each of the candidate
genes was downloaded from the NCBI database in
Genebank format and a perl script written by one of us
(GR) was used to determine the start codon, intron-exon
boundaries, branch sites and the stop codons. PCR prim-
ers flanking the exons of each of the candidate genes were
designed to amplify at least 30 bases on either end of the
exon to cover the splice site junctions. The PCR primers
used in this study are provided in Table 1. Direct sequenc-
ing of both strands was performed, and each exon was
amplified from genomic DNA of affected and unaffected
individuals, purified using the QIAGEN gel purification
system and sequenced using the BIG DYE V3.1 dideoxy-
terminator kit (Applied Biosystems). Sequence analysis
(Applied Biosystems 2001), Seqscape (Applied Biosys-
tems 2002) and Bioedit [25] software programs were used
to edit and assemble the sequences. Where a variant was
identified in only the affected individual, mutation
screening of the entire family for the variant was per-
formed to determine whether the variant was segregating
with the disease. If the sequence variant was found to be
tracking with the disease, the frequency of its occurrence
in the background population was determined. All
sequence variants occurring at a frequency of ≥ 1 % in the
background population were regarded as polymorphisms.
Results
Clinical findings
We identified a 3-generation family of northern European
descent from the KwaZulu-Natal province of South Africa.
Thirteen members were available for clinical and genetic
study, seven of whom were clinically affected. Clinical fea-
tures of the affected individuals are summarized on Table
2 and the pedigree is presented in Figure 1. The index case
(III:2) was a young male who, at 16 years, presented with
palpitations associated with ventricular tachycardia that
had left bundle branch morphology in keeping with a
right ventricular origin. His resting 12-lead electrocardio-
gram (ECG) showed an epsilon wave in lead V1 and
inverted T waves in V1-3. The echocardiogram and right
Table 3: Two-point lod scores obtained for 15 markers on chromosome 10 in the South African family with recurrence of 
arrhythmogenic right ventricular cardiomyopathy. Lod scores were calculated for different values of penetrance (a: 60%; b: 95%)
Recombination fraction
Marker Penetrance 0.00 0.01 0.05 0.10 0.20 0.30 0.40
D10S465 a -2.87 -0.94 -0.31 -0.10 0.02 0.01 -0.02
b -3.94 -1.18 -0.54 -0.32 -0.17 -0.13 -0.09
D10S547 a -6.39 -1.60 -0.34 0.09 0.34 0.31 0.17
b -8.67 -1.11 0.13 0.53 0.70 0.59 0.34
D10S1705 a 0.02 0.02 0.02 0.02 0.02 0.01 0.01
b -0.11 -0.11 -0.08 -0.06 -0.01 0.01 0.01
D10S2325 a 0.91 0.89 0.80 0.68 0.43 0.21 0.05
b 1.16 1.14 1.03 0.89 0.60 0.31 0.08
D10S1707 a 1.33 1.31 1.22 1.09 0.83 0.54 0.24
b 1.33 1.32 1.26 1.18 0.96 0.69 0.37
D10S1664 a 0.59 0.57 0.51 0.43 0.29 0.16 0.06
b 0.70 0.68 0.63 0.56 0.42 0.28 0.13
D10S191 a 2.43 2.38 2.21 1.98 1.49 0.95 0.40
b 2.93 2.88 2.68 2.43 1.88 1.26 0.61
D10S1653 a 2.43 2.38 2.21 1.98 1.49 0.95 0.40
b 2.93 2.88 2.68 2.43 1.88 1.26 0.61
D10S1477 a -2.27 -0.20 0.39 0.55 0.55 0.40 0.19
b -3.06 -0.07 0.56 0.75 0.77 0.61 0.35
D10S1661 a -1.88 0.19 0.73 0.84 0.73 0.48 0.20
b -2.28 0.68 1.21 1.28 1.11 0.77 0.37
D10S504 a 0.93 0.91 0.82 0.71 0.47 0.25 0.08
b 1.22 1.20 1.10 0.98 0.72 0.44 0.18
D10S2318 a 0.55 0.54 0.48 0.41 0.26 0.13 0.03
b 0.77 0.75 0.68 0.59 0.41 0.22 0.07
D10S548 a 1.0 0.98 0.89 0.77 0.53 0.29 0.10
b 1.29 1.26 1.17 1.05 0.79 0.49 0.21
D10S466 a -2.60 -0.57 0.02 0.20 0.24 0.15 0.06
b -3.38 -0.41 0.19 0.37 0.40 0.29 0.12
D10S245 a 0.55 0.54 0.48 0.41 0.26 0.14 0.04
b 0.84 0.82 0.75 0.67 0.48 0.29 0.11Page 6 of 10
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ventricle with reduced systolic function. He died suddenly
at the age of 22 years despite treatment with various anti-
arrhythmic drugs. His sister (III:3), who had similar clini-
cal features, died suddenly at the age of 24 years. No clin-
ical information was available for their mother (II:2) who
died of brain cancer at the age of 34 years, and their father
(II:1) was unavailable for study. The grandfather (I:1),
who is likely to be the gene carrier, died suddenly of sus-
pected coronary thrombosis at the age of 52, and the
maternal grandmother of the index case (I:2) is unaf-
fected.
A cousin of the index case (III:4) presented with chest pain
and palpitations at the age of 23 years. He had frequent
ventricular ectopy of >1000/24 hours on 24 hour ECG
(Holter) monitoring, global dilatation of the right ventri-
cle on echocardiography and angiography, changes sug-
gestive of increased amount of fat in the right ventricular
free wall with complete replacement in areas on cardiac
magnetic resonance imaging, which was confirmed on
histological examination of the right ventricle following
endomyocardial biopsy. At electrophysiological study,
inducible non-sustained monomorphic ventricular tachy-
cardia with a left bundle branch morphology and right
axis deviation was detected. The siblings of III:4 (III:6 and
III:7) were found during family screening to have struc-
tural and ECG abnormalities consistent with a diagnosis
of familial ARVC [2,26]. The mother (II:4) of subjects
III:4, III:6, and III:7 only had an abnormal ECG showing
T wave inversion in the anterior leads (V1-3), which in the
context of familial disease, is compatible with a diagnosis
of ARVC with partial penetrance [2,26]. Similarly, individ-
ual II:7 had palpitations, T wave inversion in the anterior
leads (V1-3), and mild right ventricular dilatation, aneu-
rysmal change and wall motion abnormality on cardiac
magnetic resonance imaging. Her daughter, who was
examined at age 16 (III:9) had similar cardiac magnetic
resonance imaging abnormalities, but the son (III:8) was
clinically unaffected. The pedigree indicates autosomal
dominant inheritance of ARVC with variable penetrance
(Fig. 1).
Linkage analysis
The known ARVC loci on chromosomes 14q23-q24
(ARVC1), 1q42-q43 (ARVC2), 14q12-q22 (ARVC3),
2q32.1-q32.3 (ARVC4), and 3p23 (ARVC5) were
excluded as disease loci in this family (data not shown).
Evidence for linkage was, however, detected when mark-
ers on chromosome 10p12-p14 situated close to the
ARVD6 locus were investigated. This locus had previously
been identified in a North American family displaying
ARVC as an autosomal dominant trait with complete pen-
etrance and an early age at onset [27].
The pedigree of the family is shown in Figure 1, along with
haplotypes corresponding to part of the chromosomal
region 10p12-p14. Two point lod scores for genotyping of
15 markers spanning the ARVD6 locus produced lod
scores highly suggestive of linkage in this family
(D10S191 and D10S1653; Z = 2.93 and 2.93 at θ = 0.00,
respectively, penetrance 95%; Table 3). Lod score simula-
tion analysis showed that 2.93 is the highest lod score that
could be obtained for this pedigree. It is remarkable that
the peak lod score was found at identical markers
(D10S191 and D10S1653) to the original family in which
the locus was initially described, which further supports
the external validity of our result. It was, however, not
Table 4: General information on candidate genes selected for mutation screening.
Gene symbol Genomic size No. of exons Flanking markers Function and Expression Variants detected
ITGA8 0.20 Mb 30 D10S1477, D10S191 The product of this gene is a cell surface 
glycoprotein involved in cell-to-cell 
adhesion. ITGA8 plays a major role in the 
integrin-mediated signalling pathway. It is 
expressed in skeletal muscle, fetal heart, 
and liposarcoma.
133C>A base change in exon 
17 resulting in Q276P amino 
acid change.
Two intronic changes: IVS13 -
38C>T and IVS18 +40A>G
FRMD4A 0.69 Mb 25 D10S1664, D10S2325 This gene encodes for a hypothetical 
cytoskeletal protein binding molecule 
that is concentrated in the undercoat of 
the cell-to-cell adherens junction and has 
similarity to the ERM proteins which are 
plasma membrane-actin filament cross 
linkers. Expression is increased in hepatic 
adenoma and squamous epithelium.
CA variable number tandem 
repeat (VNTR) polymorphism 
in exon 1 of the splice variant.
LAMR1P6 0.884 Kb 1 D10S600, D10S509 There is no information currently 
available on expression and function of 
this pseudogene.
346G>A base change.
Note: Echo, echocardiography; ECG, electrocardiogram; EPS, electrophysiological study; F, female; LBBB, left bundle branch block; M, male; MRI, 
magnetic resonance imaging; RV, right ventricle; VT, ventricular tachycardia; PVCs, premature ventricular complexes.Page 7 of 10
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and South African families shared similar haplotypes
because of differences in the labelling of alleles of the
markers in the two studies.
The analysis of recombination events in informative mei-
oses for the 15 markers that were genotyped in the family
facilitated the fine mapping of the locus. Construction of
haplotypes revealed that individual III:7 (who is affected;
Table 2) is recombinant for the markers D10S1477
through to D10S245 (Figure 1). In this individual the
maternally inherited chromosome had recombined. This
recombination event places the disease locus distal to
marker D10S1477. Similarly, individual III:9, who is
affected (Table 2) was found to be recombinant for mark-
ers D10S465 to D10S1707 (Figure 1). In this individual
the recombined chromosome was inherited from her
mother, II:7 who is clinically affected. These data place the
disease locus proximal to marker D10S1707. Therefore,
the critical region of the ARVD6 locus lies between mark-
ers D10S1707 and D10S1477. The typing of three addi-
tional markers within the new region, D10S1664,
D10S191 and D10S1653 did not reveal additional recom-
bination events.
The genomic sequence between markers D10S1707 and
D10S1477 was found to span a region of ~2.9 Mb and was
shown not to contain any contaminating sequence from
other chromosomes using bioinformatics analysis. The
observed ~2.9 Mb region marked a significant reduction
from ~5.4 Mb that was previously reported in the North
American family [27]. This reduction also significantly
reduced the number of possible positional candidate
genes in the region.
Bioinformatic analysis
The critical region was found to contain 21 known (pro-
tein coding) genes. Evaluation of each candidate gene for
expression and function revealed two candidate genes
with cell-to-cell adhesion properties, integrin alpha 8
(ITGA8) and FERM domain containing 4A (FRMD4A)
(Table 4). The ITGA8 gene is flanked by markers
D10S1477 and D10S191, whereas marker D10S1653 is
intragenic; markers D10S191 and D10S1653 had the
highest lod scores in the study. The marker D10S1707,
which is at the distal boundary of the ARVD6 locus,
resides within intron 4 of the FRMD4A gene. Analysis of
the gene structure of the candidate genes demonstrated
that ITGA8 is comprised of 30 exons, while FRMD4A is
comprised of 25 exons and a splice variant with 14 exons.
Only exons 1 to 4 of FRMD4A that lie within the critical
region were screened for mutations. Exon 1 of FRMD4A
was unique to the splice variant and had a variable
number of tandem repeats (VNTRs = 27 CA repeats) situ-
ated approximately 10 base pairs 5' to the start codon.
Further investigation of the microsatellite by genotyping
in affected and unaffected individuals did not show any
significant expansion or reduction of the repeats, which
could be considered as a possible disease causing mecha-
nism.
The LAMR1P6 pseudogene/retroposon (XM_053952) is a
processed transposable element that is reported to occur
within the ARVC6 critical interval [6]. However, the local-
isation of LAMR1P6 pseudogene/retroposon in our inter-
val could not be verified, and has been placed 11.9 Mb
outside the ARVC6 critical region (Celera Genome Map).
The recent finding of a functional lamr1 retroposon as a
cause of ARVC in the mouse and the possibility that an
expressed pseudogene may regulate the messenger RNA
stability of a homologous gene [28] suggest that the
LAMR1P6 pseudogene/retroposon is a plausible candi-
date for ARVC in man. The fact that the related functional
homologue LAMR1P6 is involved in apoptosis, which is
thought to be an important pathogenic mechanism of
ARVC, led us to screen for the LAMR1P6 pseudogene on
chromosome 10p for mutations in this study.
Mutation analysis
Data on the three candidate genes and all the variants
detected in this study are summarised in Table 4. Direct
sequencing of the candidate genes did not reveal any path-
ogenic mutations in neither the coding nor intron-exon
junctions of affected individuals. A single nucleotide pol-
ymorphism (SNP) Q276P in ITGA8, was detected in the
coding sequence of exon 17, and was found to co-segre-
gate with the disease-associated haplotype in the family.
Further investigation revealed that this SNP was present in
6 out of 314 chromosomes from the normal population,
suggesting that it is a polymorphism. Mutation screening
of the LAMR1P6 pseudogene revealed a single nucleotide
polymorphism (346G>A) that was present in both
affected and non-affected members of the family.
Discussion
We report a South African family with ARVC segregating
as an autosomal dominant trait for which we obtained lod
scores highly suggestive of linkage to the ARVC6 locus on
chromosome 10p12-p14 [27]. Unlike the original family
in which linkage had been initially reported who demon-
strated complete penetrance of the disease at an early age,
we found variable expression of the disease with a ten-
dency for severe manifestations in the third generation. In
addition, we have defined crossover events that have sig-
nificantly reduced the chromosomal region harbouring
the disease gene to a 2.9 Mb interval between markers
D10S1707 and D10S1477.
The refined chromosomal region of interest on chromo-
some 10p contains several candidate genes that we arePage 8 of 10
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considered previously as a good candidate [27] is no
longer a positional candidate for the ARVD6 locus as
defined by our haplotyping data. We screened the posi-
tional candidate genes, ITGA8 and FRMD4A, and the
LAMR1P6 pseudogene since these genes are known to
play a role in mediating either cell-extracellular matrix
and cell-cell interactions or apoptosis. ITGA8 belongs to
the integrin alpha chain family, and is a receptor for
fibronectin and cytostatin, and recognizes the sequence R-
G-D in its ligands. FRMD4A is highly concentrated in the
undercoat of the cell-to-cell adherens junction and has
similarity to the ERM proteins which are plasma mem-
brane-actin filament cross linkers [29]. LAMR1 (also
known as RPSA) is a ribosomal protein found in the
nucleus and is involved in apoptosis [6]. The LAMR1P6
pseudogene may possibly play an important role in regu-
lating the translational process by ensuring the stability of
the messenger RNA of the wildtype LAMR1 gene. Such a
mechanism has been characterized in mice whereby
reduced transcriptional levels of makorin1-p1 result in
reduced shelf-life of its homologue, makorin1 [28].
Mutation screening of the coding regions and intron-exon
boundaries of ITGA8, FRMD4A and LAMR1P6 revealed
only non-pathogenic changes. LAMR1P6 was excluded as
being responsible for the disorder in this kindred as the
only sequence variant detected was found in both affected
and unaffected individuals. The presence of mutations in
the regulatory regions of ITGA8 and FRMD4A genes, as
has been reported in the case of ARVC1 and the TGFβ3
gene [5], cannot be ruled out.
The lod scores obtained in the current study did not reach
the statistical threshold of significance of 3. However, the
fact that this locus has previously been linked to ARVC
with a lod score over 3, at the same markers (D10S191
and D10S1653; [27]) for which we have obtained our
highest lod scores, supports the assertion of genetic link-
age in this South African family. Additionally, the com-
bined evidence provided in this manuscript of a disease-
associated haplotype spanning 15 markers on chromo-
some 10p, as well as the fact that the maximum lod score
that could be achieved for this family was obtained for
two markers, is highly suggestive of linkage in this family.
The narrowing of the ARVD6 critical interval has
improved the prospects for the identification of the causal
gene for ARVC6. Once the gene and mutation are identi-
fied, it is possible that improved therapeutic options
based on the underlying cause of disease may be devel-
oped, resulting in better long term care and survival for
patients with ARVC and their family members who are at
risk.
Conclusion
We report a new family of northern European descent
with ARVC segregating as an autosomal dominant trait
that is potentially linked to the ARVD6 locus on chromo-
some 10p12-14. As this condition is rare with only a few
relatively small families with ARVC reported around the
world, it is important to provide independent corrobora-
tion for the ARVC loci. Reduction of the ARVC6 critical
interval will improve the feasibility of the identification of
the disease causing gene.
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